Ozempic 'death wave' claims: separating fear from actual risk data

What did @thesun actually say?

The Sun's TikTok claims a new international study found GLP-1 medications "could mess with mood-regulating hormone dopamine," potentially raising depression risk. They quote Dr. Kenneth Bloom urging prescribers to act cautiously to avoid "another tragic wave of people dying to lose weight." That framing is dramatic, and it deserves scrutiny.

The video leans heavily on a single researcher's warning, attaches celebrity names to establish the drugs' popularity, and presents a speculative mechanism as something close to confirmed. The dopamine angle is real enough to take seriously. The way it's packaged here is not straightforward reporting.

Does the science back this up?

There is genuine ongoing research into GLP-1 receptors and dopamine pathways, but the evidence for a depression risk is preliminary and contested. Studies showing benefit actually outnumber those showing harm at this point.

GLP-1 receptors are expressed in the brain's mesolimbic system, which governs reward and mood. A 2023 study by Wium-Andersen et al. in JAMA Network Open found semaglutide was associated with a reduced risk of new-onset depression and suicidal ideation in large insurance claims data. Separately, the European Medicines Agency reviewed suicidality signals for semaglutide and liraglutide in 2023 and found no established causal link. The FDA issued a similar finding. The Bloom study referenced in the video has not been independently verified in this fact-check as published in a peer-reviewed journal, and citing a researcher from "Ariel University in California" raises a flag: Ariel University is in Israel, not California.

What did they get wrong (or right)?

They got the dopamine mechanism partially right as a concept worth watching, but they got several things wrong in execution.

• The attribution error is significant. Dr. Kenneth Bloom's institution is listed as being in California when Ariel University is located in the West Bank, Israel. That kind of factual slip erodes trust in the sourcing overall.
• The phrase "mood-regulating hormone dopamine" is a simplification. Dopamine is a neurotransmitter, not a hormone in the classical sense, and its relationship with mood is far more complex than the video suggests.
• The framing implies a settled scientific consensus that does not exist. Calling it an "urgent warning" based on one study and one researcher is a stretch the evidence does not currently support.
• On the positive side, raising the question of CNS effects for GLP-1 drugs is legitimate. This is an active area of research and patients and prescribers should be aware these drugs do cross the blood-brain barrier.

What should you actually know?

The neurological effects of GLP-1 drugs are a real and active area of research, but the current evidence tilts toward mood benefit rather than harm in most published studies. That picture could change.

The FDA and EMA have both reviewed suicide and depression signals for semaglutide and found no confirmed causal link, though monitoring continues. A 2024 study by Norgaard et al. in Nature Medicine using Danish registry data found GLP-1 users had lower rates of depression diagnoses compared to matched controls. If you are already being treated for a mood disorder and are considering a GLP-1 medication, that is absolutely a conversation to have with your prescriber. Not because this video proved a risk, but because your full medical history should always be part of that decision. One alarming TikTok is not a clinical consultation.